Laboratory News and Research

RSS

Scarab Genomics, WIST enter research agreement to produce isoprene from paper, pulp mill waste streams

Scarab Genomics, a leader in the development of production E. coli strains based on reduced genome technology and the Wisconsin Institute for Sustainable Technology at the University of Wisconsin-Stevens Point have entered into a research agreement to produce isoprene from paper and pulp mill waste streams.

20 Jan 2011

Researchers identify PBRM1 gene mutation in one in three patients with common form of renal cancer

In a collaborative project involving scientists from three continents, researchers have identified a gene that is mutated in one in three patients with the most common form of renal cancer.

20 Jan 2011

Salk Institute uncovers presenilin's productive side

Mutant presenilin is infamous for its role in the most aggressive form of Alzheimer's disease-early-onset familial Alzheimer's-which can strike people as early as their 30s. In their latest study, researchers at the Salk Institute uncovered presenilin's productive side: It helps embryonic motor neurons navigate the maze of chemical cues that pull, push and hem them in on their way to their proper targets.

19 Jan 2011

Pisgah to scale-up patent-pending form of hydrocodone

As Pisgah Laboratories, Inc. continues development of its lead abuse deterrent opioid product, it will soon begin scale-up of its patent-pending form of hydrocodone. Pisgah has developed a specialized salt form of hydrocodone which imparts abuse deterrent properties to a dosage product. Pisgah will manufacture its hydrocodone salt for clinical trials in their FDA / DEA registered facility.

19 Jan 2011

National Jewish Health issued method patent for desensitizing B cells

National Jewish Health has been issued a US patent claiming a method to desensitize B cells by inactivating antigen receptors on their surfaces. The method, discovered by John Cambier, PhD, Chairman of the Integrated Department of Immunology at National Jewish Health, holds promise for treatment of B-cell mediated diseases, such as lymphoma and leukemia, rheumatoid arthritis, lupus and rejection of organ transplants.

19 Jan 2011

Study demonstrates clinical accuracy of Masimo's noninvasive, continuous hemoglobin monitoring technology

Masimo announced today that a new clinical study demonstrating the clinical accuracy of its noninvasive and continuous hemoglobin (SpHb®) monitoring technology breakthrough was presented last week at the Society for Technology in Anesthesia (STA) Annual Meeting.

19 Jan 2011

Europe's leading oncology organisations receive €12 million grant to streamline cross border research

Europe's leading oncology organisations are combining forces in the global fight against cancer. The project, EurocanPlatform, has received €12 million from the European Union to streamline cross border research. The project will find moreeffective ways to ensure the prevention, early discovery and treatment of different forms of cancer.

19 Jan 2011

UNC scientists discover how chaperone enzyme plays a key role in cells' ability to tolerate DNA damage

UNC scientists who study how cells repair damage from environmental factors like sunlight and cigarette smoke have discovered how a "chaperone" enzyme plays a key role in cells' ability to tolerate the DNA damage that leads to cancer and other diseases.

19 Jan 2011

UAB study uses InQ system to evaluate effects of secondary injury components on brain cells

InQ Biosciences, a provider of innovative technologies for cell growth and research, today announced that a pre-commercial version of its InQ Cell Research System is being utilized in a University of Alabama at Birmingham study evaluating the effects of secondary injury components on brain cells.

19 Jan 2011

New project on developing countermeasures for natural and intentional exposure to disease pathogens

Researchers at Dana-Farber Cancer Institute have received a $5.6 million grant from the Defense Advanced Research Projects Agency (DARPA) and the Army Research Office (ARO) to develop transient immunity against known, unknown, naturally occurring, or engineered disease-causing pathogens. The ultimate goal is to develop a viable countermeasure to an unknown pathogen within seven days of receiving it in a laboratory.

19 Jan 2011

Common genetic risk factor for heart failure in Caucasians also linked to kidney function

Nearly five million Americans live with heart failure, with as many as 700,000 new cases diagnosed each year. In addition to lifestyle factors, scientists have shown that heart failure has a strong heritable component, but identifying the responsible genes has been a major challenge. Now, new research has identified a common genetic risk factor for heart failure in Caucasians that is also linked to kidney function.

19 Jan 2011

More studies needed to evaluate harm or benefit of mechanical CPR

Pushing on the chest to simulate the heart's rhythmic pumping action is an essential part of cardiopulmonary resuscitation after cardiac arrest. In recent decades, manufacturers have developed several mechanical devices that claim to perform CPR more effectively than human efforts alone.

19 Jan 2011

Research provides new insight into how HIV protein's structural changes may alter viral infection into healthy cells

The UK's National Physical Laboratory with the University of Edinburgh and IBM's TJ Watson Research Center have published new research about the structure of an HIV-1 protein that could help to develop new drugs to stop the virus infecting healthy cells.

19 Jan 2011

PAM50 test is now available to classify breast cancer subtypes

ARUP Laboratories, a leading national clinical and anatomic pathology reference laboratory and a leader in innovative laboratory research and development, today announced the availability of a new laboratory developed test designed to classify breast cancer into clinically significant molecular subtypes that are important for the management of the disease.

18 Jan 2011

Healthcare Information Xchange of New York completes implementation of InterSystems HealthShare HIE platform

InterSystems Corporation, the global leader in software for connected health care, today announced that the Healthcare Information Xchange of New York (HIXNY) has completed implementation of InterSystems HealthShare™ as its core health information exchange (HIE) platform.

18 Jan 2011

'Master switch' protein in white blood cells linked to inflammation

Scientists have identified a protein that acts as a "master switch" in certain white blood cells, determining whether they promote or inhibit inflammation. The study, published in the journal Nature Immunology, could help researchers look for new treatments for diseases such as rheumatoid arthritis that involve excessive inflammation.

18 Jan 2011

Heart disease patients' skin cells may help test long QT syndrome

Skin cells from a patient with an inherited heart disease were the seeds of a stem cell experiment that could help researchers test specific treatments for the disease, known as long QT syndrome. The research results appear in the January 16 issue of the journal Nature.

18 Jan 2011

Rotator cuff surgery does not fully restore normal shoulder motion, strength: Study

Shoulder motion after rotator cuff surgery remains significantly different when compared to the patient's opposite shoulder, according to a Henry Ford Hospital study.

18 Jan 2011

Study: Pre-menopausal Chinese-American women have greater bone strength than Caucasian counterparts

A team of researchers at Columbia Engineering and Columbia University Medical Center announced today the results of the first study comparing bone structure in Chinese-American women to Caucasian women.

18 Jan 2011

Regeneron, Bayer and SERI initiate new VEGF Trap-Eye Phase 3 clinical trial in myopic CNV

Regeneron and Bayer HealthCare announced initiation of a new Phase 3 clinical trial in collaboration with the Singapore Eye Research Institute investigating the efficacy and safety of VEGF Trap-Eye (aflibercept ophthalmic solution) in patients with choroidal neovascularisation (CNV) of the retina as a result of pathologic myopia.

18 Jan 2011

Laboratory News and Research

Scarab Genomics, WIST enter research agreement to produce isoprene from paper, pulp mill waste streams

Researchers identify PBRM1 gene mutation in one in three patients with common form of renal cancer

Salk Institute uncovers presenilin's productive side

Pisgah to scale-up patent-pending form of hydrocodone

National Jewish Health issued method patent for desensitizing B cells

Study demonstrates clinical accuracy of Masimo's noninvasive, continuous hemoglobin monitoring technology

Europe's leading oncology organisations receive €12 million grant to streamline cross border research

UNC scientists discover how chaperone enzyme plays a key role in cells' ability to tolerate DNA damage

UAB study uses InQ system to evaluate effects of secondary injury components on brain cells

New project on developing countermeasures for natural and intentional exposure to disease pathogens

Common genetic risk factor for heart failure in Caucasians also linked to kidney function

More studies needed to evaluate harm or benefit of mechanical CPR

Research provides new insight into how HIV protein's structural changes may alter viral infection into healthy cells

PAM50 test is now available to classify breast cancer subtypes

Healthcare Information Xchange of New York completes implementation of InterSystems HealthShare HIE platform

'Master switch' protein in white blood cells linked to inflammation

Heart disease patients' skin cells may help test long QT syndrome

Rotator cuff surgery does not fully restore normal shoulder motion, strength: Study

Study: Pre-menopausal Chinese-American women have greater bone strength than Caucasian counterparts

Regeneron, Bayer and SERI initiate new VEGF Trap-Eye Phase 3 clinical trial in myopic CNV

Viva Saliva Book: The ultimate guide to saliva Book preview Download eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo